BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice